| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA858: Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma |
|
Medicine details |
|
| Medicine name | lenvatinib (Kisplyx®) |
| Formulation | 4 mg and 10 mg hard capsules |
| Reference number | 3403 |
| Indication | In combination with pembrolizumab for the first-line treatment of advanced renal cell carcinoma in adults |
| Company | Eisai Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/12/2021 |
| NICE guidance | TA858: Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma |